Xarelto matches standard in head-to-head blood clot trial

Citing long-term trial results, Germany's Bayer says that its top pipeline prospect, rivaroxaban (Xarelto), was just as effective as warfarin combined with Lovenox in preventing blood clots and did not raise the risk of bleeding. The data puts Bayer on a fast track toward an application to use the drug to prevent strokes as well as deep vein thrombosis, indications that could help build billions of dollars in annual revenue. "The results of this study confirm that the novel, convenient...